



Uploaded to VFC Website

▶▶▶ February 2013 ◀◀◀

This Document has been provided to you courtesy of Veterans-For-Change!

Feel free to pass to any veteran who might be able to use this information!

For thousands more files like this and hundreds of links to useful information, and hundreds of "Frequently Asked Questions, please go to:

[Veterans-For-Change](#)

*Veterans-For-Change is a 501(c)(3) Non-Profit Corporation
Tax ID #27-3820181*

If Veteran's don't help Veteran's, who will?

We appreciate all donations to continue to provide information and services to Veterans and their families.

https://www.paypal.com/cgi-bin/webscr?cmd=_s-xclick&hosted_button_id=WGT2M5UTB9A78

Note:

VFC is not liable for source information in this document, it is merely provided as a courtesy to our members.



Mixed Connective Tissue Disease

[View the current Mixed Connective Tissue Disease InDepth page on BioPortfolio.com](http://www.bioportfolio.com/indepth/Mixed_Connective_Tissue_Disease.html) ([PDF](#))

(http://www.bioportfolio.com/indepth/Mixed_Connective_Tissue_Disease.html) - Regularly Updated.

Mixed Connective Tissue Disease Clinical Trials:



- [Characteristics and Disease Progression of Mixed Connective Tissue Disease and Systemic Lupus Erythematosus](#)

Mixed Connective Tissue Disease Patents:



- 7517529- [Treatment of type I diabetes](#)
- 7557135- [Inhibitors of cytosolic phospholipase A.sub.2](#)
- 7557190- [Optimized proteins that target Ep-CAM](#)
- 7560112- [Anti-il-6 antibodies, compositions, methods and uses](#)
- 7560247- [Nucleic acids encoding anti-IL-12 antibodies, and methods of production](#)
- 7563869- [Substance specific to human PD-1](#)
- 7566703- [Semi-soft C-class immunostimulatory oligonucleotides](#)
- 7566713- [Immuno inhibitory heterocyclic compounds](#)
- 7569384- [Albumin fusion proteins](#)
- 7576177- [Hsp peptides and analogs for modulation of immune responses via antigen presenting cells](#)
- 7579324- [Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof](#)
- 7553816- [p-amidobenzylethers in drug delivery agents](#)
- 7550142- [Anti-integrin antibodies, compositions, methods and uses](#)
- 7547767- [Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses](#)
- 7517890- [GTPase inhibitors and methods of use](#)
- 7521424- [Albumin fusion proteins](#)

- 7521446- [Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith](#)
- 7521542- [Humanized Fc.gamma.RIIB-specific antibodies and methods of use thereof](#)
- 7528111- [Method of vaccinating subjects receiving immune modulating therapy](#)
- 7534440- [Fusion molecules and methods for treatment of immune diseases](#)
- 7537762- [Human monoclonal antibodies to activin receptor-like kinase-1](#)
- 7541441- [Antibodies that specifically bind to TL5](#)
- 7544669- [Polynucleotide therapy](#)
- 7544713- [Compounds and methods for delivery of prostacyclin analogs](#)
- 7579439- [Modulation of IL-2- and IL-15-mediated T cell responses](#)
- 7582313- [Methods of organ regeneration using Hox 11-expressing pluripotent cells](#)
- 7612064- [Sulfoyrroles](#)
- 7612080- [GTPase inhibitors and use thereof for controlling platelet hyperactivity](#)
- 7612181- [Dual variable domain immunoglobulin and uses thereof](#)
- 7612182- [Anti-IL-6 antibodies, compositions, methods and uses](#)
- 7615552- [Fused heterocyclic compounds](#)
- 7622451- [Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders](#)
- 7622486- [Pyridine compounds, process for their preparation and compositions containing them](#)
- 7625882- [Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders](#)
- 7628988- [Methods and compositions for treating type 1 diabetes](#)
- 7632497- [Engineering Fc Antibody regions to confer effector function](#)
- 7611708- [Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies](#)
- 7608704- [Secreted proteins](#)
- 7608683- [Stress proteins and peptides and methods of use thereof](#)
- 7585840- [Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease](#)
- 7592010- [Albumin fusion proteins](#)
- 7592422- [Modified plasminogen activator inhibitor type-1 and methods based thereon](#)
- 7597886- [Tumor necrosis factor-gamma](#)
- 7598067- [PDEs and uses thereof](#)
- 7598244- [\[1,2,4\]triazolo\[1,5,a\]pyrimidin-2-ylurea derivative and use thereof](#)
- 7598247- [Immunomodulating heterocyclic compounds](#)
- 7601335- [Pretreatment of a biological sample from an autoimmune disease subject](#)
- 7605236- [Antibodies that immunospecifically bind to B lymphocyte stimulator protein](#)
- 7608392- [Diagnostic assay for measuring a cell mediated immune response](#)
- 7634317- [Techniques for applying, calibrating, and controlling nerve fiber stimulation](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road,

